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Background:  The risk of hyperkalemia (HK) often precludes use of mortality-reducing, guideline-based heart failure (HF) therapy with renin-
angiotensin-aldosterone system (RAAS) blockers and/or `-blockers, particularly among those with chronic kidney disease (CKD). The oral potassium 
(K+)-binding polymer, RLY5016, 30 g/d, significantly reduced the incidence of HK in patients with HF and CKD in a prior controlled trial.
Methods:  Sixty-three patients with HF and CKD on HF therapy, mean serum K+ of 4.8 mEq/L, and eGFR of 46 mL/min/1.73 m2, were started on 
spironolactone (SP) 25 mg/d which was uptitrated to 50 mg/d if K+ was <5.1 mEq/L. Simultaneously, RLY5016 20 g/d was started with up or down 
titration allowed in 10 g/d increments from 0-60 g/d over 8 weeks to keep K+ in the target range of 4.0 - 5.1 mEq/L. The primary endpoint was 
maintenance of K+ in the normal range of 3.5 - 5.5 mEq/L. All analyses used central lab K+ while local lab K+ was used for titration.
Results:  Fifty-seven patients (90%) maintained K+ in the normal range 3.5-5.5 mEq/L at the end of the study and 48 (76%) during the entire 
study treatment. Hypokalemia (<3.5 mEq/L) at any visit was observed in 1 (2%) patient and HK (>5.5 mEq/L) in 15 (24%) patients by central lab. 
RLY5016 was titrated 0, 1, and ≥ 2 times in 32%, 21%, and 47% patients, respectively, keeping K+ in the target range over 8 weeks. All patients 
were successfully uptitrated to SP 50 mg/d by Day 14. The mean dose of RLY5016, eGFR, and K+ on the last day of treatment was 24 g/d, 46 mL/
min/1.73 m2, and 4.6 mEq/L, respectively. Two patients were withdrawn due to adverse effects of diarrhea and vomiting and 2 due to acute renal 
failure, both reported as unrelated to RLY5016 (K+ 4.2 mEq/L 24h prior to the event and K+ 6.0 mEq/L at the time of the event, but blood pH 7.17, 
respectively). One on-treatment (unwitnessed) death occurred within 24h of a serum K+ 4.6 mEq/L.
Conclusions:  In this high-risk HF population with CKD, on background therapy with RAAS inhibitors, -blockers, and SP, dose titration with 
RLY5016 allowed successful maintenance of serum K+ in the normal range and may thereby enable more of these patients to benefit from mortality-
reducing therapies. 
